Switching to biosimilar infliximab produces similar results, study finds
A new study has been published in The Lancet comparing the effect of switching to the biosimilar Inflectra (infliximab-dyyb), marketed by US pharma giant Pfizer (NYSE: PFE), with continued treatment from reference product Remicade (infliximab).
The research, which involved 482 individuals and allowed for a margin of inferiority of up to 15%, was not designed to demonstrate non-inferiority in individual diseases.
Researchers looked at patients with autoimmune disorders such as rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis and Crohn's disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze